The National Cancer Institute has issued an interim guidance for all NCTN and NCORP cancer trials given the impact the COVID-19 outbreak is having on hospitals.

You can read the guidance here.

The NCI also issued another guidance for patients on Division of Cancer Prevention trials. You can read that document here.

These documents will be continually updated by the CIRB as more information becomes available. Keep checking the CIRB webpage for announcements and for their FAQ about treating patients on NCI cancer trials in the context of the coronovirus pandemic.

Other Recent Stories

myeloMATCH: precision medicine in myeloid cancer
Oct 23, 2024
myeloMATCH precision medicine trials in myeloid leukemias open to patient enrollment across U.S. and Canada
S1826 article heading
Oct 16, 2024
Longer-term data from SWOG S1826 trial confirm nivolumab-AVD benefit in Hodgkin lymphoma